Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Published:2023-04 Issue: Volume: Page:
ISSN:2173-5808
Container-title:Neurología (English Edition)
language:en
Short-container-title:Neurología (English Edition)

Author:

Meca-Lallana J.E.,Álvarez-Cermeño J.C.,Casanova Estruch B.,Izquierdo Ayuso G.,Ortiz Castillo R.,Rodríguez-Antigüedad A.,Calles Hernández C.

Funder

Sanofi

Publisher

Elsevier BV

Subject

Industrial and Manufacturing Engineering,Materials Science (miscellaneous),Business and International Management

Reference21 articles.

1. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies;Wingerchuk;Mayo Clin Proc,2014

2. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial;Cohen;Lancet,2012

3. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis;Coles;N Engl J Med,2008

4. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial;Coles;Neurology,2012

5. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial;Coles;Lancet,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP